Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE)
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Article Information
- Received January 8, 2019
- Accepted in final form June 13, 2019
- First Published August 6, 2019.
Author Disclosures
- William Camu, MD, PhD,
- Philippe Lehert, PhD,
- Charles Pierrot-Deseilligny, MD,
- Patrick Hautecoeur, MD,
- Anne Besserve, MD,
- Anne-Sophie Jean Deleglise, MD,
- Marianne Payet, MD,
- Eric Thouvenot, MD, PhD and
- Jean Claude Souberbielle, MD
- William Camu, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Actelion, Effik, Merck, MedDay pharmaceuticals, Novartis pharma, Roche and, SANOFI
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Philippe Lehert, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Charles Pierrot-Deseilligny, MD,
NONE
NONE
Novartis Pharma for travel and accommodation expenses (for the annual AAN congress) in 2014 and 2015
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Patrick Hautecoeur, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anne Besserve, MD,
NONE
NONE
NONE
NONE
NONE
NONE
I am currently an employee of MERCK as Clinical Research Manager since 2013.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anne-Sophie Jean Deleglise, MD,
NONE
NONE
NONE
NONE
NONE
NONE
Medical Director at Merck France
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marianne Payet, MD,
NONE
NONE
NONE
NONE
NONE
NONE
I am an employee of Merck, as Medical advisor since 2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eric Thouvenot, MD, PhD and
(1) Biogen Idec (2) Merck Serono (3) Sanofi Genzyme (4) Novartis (5) Roche (6) Actelion
NONE
Received honoraria for invited lectures from Genzyme, Biogen, Novartis, Merck-Serono and Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen Idec (2) Novartis (3) Roche
(1) PHRC national 2012 (NCT01817166)
NONE
(1) ARSEP
NONE
NONE
NONE
NONE
NONE
NONE
- Jean Claude Souberbielle, MD
NONE
NONE
speaker honoraria for mylan, diasorin, roche diagnostics, MSD, Lilly,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From CHU Gui de Chauliac (W.C.) and Institut de Génomique Fonctionnelle (E.T.), Université de Montpellier, France; Faculty of Economics (P.L.), UCL Mons, Louvain, Belgium; Faculty of Medicine (P.L.), the University of Melbourne, Australia; CHU Pitié Salpêtrière (C.P.-D.), Paris; GHICL St Vincent de Paul (P.H.), Lille; Merck (A.B., A.-S.J.-D., M.P.), Lyon; CHU Caremeau (E.T.), Nîmes; and CHU Necker (J.C.S.), Paris, France.
- Correspondence
Dr. Camu w-camu{at}chu-montpellier.fr
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Alert Me
Recommended articles
-
Null Hypothesis
Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1aRaymond Hupperts, Joost Smolders, Reinhold Vieth et al.Neurology, October 08, 2019 -
Articles
Key issues in the diagnosis and treatment of multiple sclerosisAn overviewPaul O’Connor et al.Neurology, September 24, 2002 -
Articles
Cladribine and progressive MSClinical and MRI outcomes of a multicenter controlled trialGeorge P. A. Rice, Massimo Filippi, Giancarlo Comi et al.Neurology, March 14, 2000 -
Articles
The Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosisJ. H. Noseworthy, P. O'Brien, B. J. Erickson et al.Neurology, November 01, 1998